TetraLogic closes private offering with institutional investors
PDF: 6.16.14 TetraLogic Convertible
For Immediate Release
June 24, 2014
SAN DIEGO, CA – WBB Securities acted as co-manager on a convertible senior notes transaction for TetraLogic
Pharmaceuticals, Inc., a clinical phase biopharmaceutical company focused on discovering and developing novel
small molecule therapeutics for oncology and infectious disease. Tetralogic announced the pricing of the
offering to institutional investors on June 17, 2014. Today the company announced the closing of the
transaction, raising an aggregate of $47 million before fees and expenses.
TetraLogic intends to use the proceeds for general corporate purposes including the continued development of its
lead compounds and other related research and development.
About WBB Securities
WBB Securities is a leading investment management, investment banking, and equity research firm.
Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent
broker dealer and investment advisor with proprietary trading desks that have market-making capabilities.
WBB Securities has built a nationwide team of respected senior investment and research professionals with a
network of branches throughout the US serving institutional and high net worth clients. The firm also maintains
an investment banking and equity research practice focused exclusively in the life sciences
niche. www.wbbsec.com
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small
molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates
in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical
trials for hematological malignancies and solid tumors. SHAPE is entering Phase 2 trials for early-stage
Cutaneous T-Cell Lymphoma. www.tetralogicpharma.com
